Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Opticept Technologies AB has 1 pending office action in Biotechnology & Pharmaceuticals. PAK, JOHN D is identified as the busiest examiner, and the examination record is concentrated in a single examiner and art-unit setting. The profile gives the company a defined prosecution channel for its biotechnology and pharmaceutical subject matter.
The response should connect the claims to the disclosed biological mechanism, composition, or process and address the examiner’s specific grounds with evidence appropriate to the technology. A focused assignment can support consistent terminology across the response and later amendments. The data does not show multiple examination groups, so counsel can prioritize direct resolution of the recorded action rather than broader coordination across separate prosecution teams.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 1 | 52.4% | +37.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030739 | A METHOD FOR TREATING A BIOLOGICAL MATERIAL | PAK, JOHN D | 51d overdue |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030739 | A METHOD FOR TREATING A BIOLOGICAL MATERIAL | PAK, JOHN D | 1699 | §103§112DP | Non-Final OA | 51d overdue | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOpticept Technologies AB has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
John D Pak has the most, with 1 of Opticept Technologies AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.